XERS FY2025 SEC EDGAR DEF 14A #56 of 168 in industry

Xeris Biopharma Holdings, Inc. CEO pay ratio

The CEO earned $16.9M in FY2025 against median worker pay of $232,022 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
IL
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#56/168

Data updated August 2026

Subscribe to Xeris Biopharma Holdings, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
73:1
Moderate (Scale: 0–1000:1)
CEO pay
$16.9M
Median worker
$232,022

Answer first

Xeris Biopharma Holdings, Inc.'s FY2025 CEO total of $16.9M ranks #233 of 1,423 complete filings; its 73:1 pay ratio ranks #809. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $232,022. Industry placement uses the FY2025 SIC-28 peer cohort (# 56 of 168, 67th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#233
$16.9M of 1,423 FY2025
Ratio rank
#809
73:1 of 1,423
Industry pct
67th
above the industry median pay ratio

How Xeris Biopharma Holdings, Inc. ranks nationally

Xeris Biopharma Holdings, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$16,937,606 Top 16% higher than 84% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). This entry sits in this band. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Xeris Biopharma Holdings, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($16.9M) against pay ratio (73:1) for Xeris Biopharma Holdings, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7015949.311875670.916735392.521595114.126454835.840.3:149.6:159:168.3:177.7:1CEO total payPay ratio (CEO : median worker)Xeris Biopharma Holdings, Inc., CEO total pay: 16937606 · Pay ratio (CEO : median worker): 73:1Xeris Biopharma Holdings, Inc.Chemours Co, CEO total pay: 8600301 · Pay ratio (CEO : median worker): 71:1Chemours CoUNITED THERAPEUTICS Corp, CEO total pay: 18042856 · Pay ratio (CEO : median worker): 76:1UNITED THERAPEUTICS CorpJazz Pharmaceuticals plc, CEO total pay: 19418256 · Pay ratio (CEO : median worker): 69:1Jazz Pharmaceuticals plcTg Therapeutics, Inc., CEO total pay: 25571250 · Pay ratio (CEO : median worker): 67:1Tg Therapeutics, Inc.
Xeris Biopharma Holdings, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Xeris Biopharma Holdings, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Xeris Biopharma Holdings, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
73:1
FY2025
vs prior FY
-9:1
from FY2024 82:1
CEO $ YoY
-3.8%
$16.9M latest
Filings shown
2
FY2024–2025
Xeris Biopharma Holdings, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $17.6M - $214,795 82:1 -
2025 $16.9M -3.8% $232,022 73:1 -9:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1867096, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
73:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$16.9M
Companies in Industry
168
vs. Industry Median
Above
#56 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Xeris Biopharma Holdings, Inc.: MODEST · PEAK pay ratio

Xeris Biopharma Holdings, Inc.'s FY2025 ratio 73:1 ranks #56 of 168 Chemicals & Pharmaceuticals filers (67th percentile). the CEO earned 73× the median employee ($232,022) in FY2025.

Median employee $232,022 (ELITE-MED); MODEST · PEAK stamps put about 73 median-wage years per CEO year.

CEO Total Pay

$16.9M

FY2025 Summary Compensation, well above median

Pay Ratio

73:1

Near industry median

Xeris Biopharma Holdings, Inc. in the higher Chemicals & Pharmaceuticals third

Xeris Biopharma Holdings, Inc.'s FY2025 ratio 73:1 ranks #56 of 168 Chemicals & Pharmaceuticals filers (67th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Xeris Biopharma Holdings, Inc.'s $16.9M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #233 and ratio rank #809 split - treat 73:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$16.9M
Median Employee Pay
$232,022
Pay Ratio
73:1
Filing Date
2026-04-23

Company Info

Ticker
XERS
CIK
1867096
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
IL
View SEC filings →
SEC EDGAR DEF 14A for CIK 1867096, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Xeris Biopharma Holdings, Inc.'s FY2025 ratio 73:1 ranks #56 of 168 Chemicals & Pharmaceuticals filers (67th percentile).

Read with Xeris Biopharma Holdings, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · PEAK · ELITE-MED.

Manhattan Associates Inc · PEAK

ABS(ceo_total_comp) peer at $16.9M (Δ $5K heavier vs Xeris Biopharma Holdings, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
SentinelOne, Inc. · PEAK

ABS(ceo_total_comp) peer at $16.9M (Δ $11K lighter vs Xeris Biopharma Holdings, Inc.); MID · ELITE-MED vs this page's MODEST · PEAK · ELITE-MED.
Liberty Latin America Ltd. · PEAK

ABS(ceo_total_comp) peer at $16.9M (Δ $53K lighter vs Xeris Biopharma Holdings, Inc.); HIGH · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Otis Worldwide Corp · PEAK

ABS(ceo_total_comp) peer at $17.0M (Δ $53K heavier vs Xeris Biopharma Holdings, Inc.); STEEP · PAR-MED vs this page's MODEST · PEAK · ELITE-MED.
Chemours Co (SIC 28 pole)

Chemours Co stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Xeris Biopharma Holdings, Inc.'s MODEST filing.
National dual ranks · #233/#809

Xeris Biopharma Holdings, Inc.'s FY2025 package sits #233 by CEO dollars and #809 by ratio under PEAK · MODEST.
Ratio primer · MODEST

Xeris Biopharma Holdings, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Xeris Biopharma Holdings, Inc. (CIK 1867096), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.